

Appendix 4. Dynamic change on discriminations of risk predicting models since initiation of AVT until on-treatment year 5. The figure revealed that from the initiation of AVT until year 5, a steadily decreasing trend on AUROC was observed for all models when using serial on-treatment variables.

Note: Data using baseline (Year 0)¹ and on-therapy variables² during the first two years (Year 0.5 to year 2) have been ever published on: Reference 1: Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, et al. Hepatocellular carcinoma prediction models in chronic hepatitis B: A systematic review of 14 models and external validation. *Clin Gastroenterol Hepatol* 2021;19:2499-2513.

Reference 2: Wu S, Zhou J, Wu X, Sun Y, Wang B, Kong Y, et al. Comparative performance of 14 HCC prediction models in CHB: A dynamic validation at serial on-treatment timepoints. *Am J Gastroenterol* 2022;117:1444-1453.

